270 related articles for article (PubMed ID: 20934501)
1. New chimeric advanced Drug Delivery nano Systems (chi-aDDnSs) as doxorubicin carriers.
Gardikis K; Tsimplouli C; Dimas K; Micha-Screttas M; Demetzos C
Int J Pharm; 2010 Dec; 402(1-2):231-7. PubMed ID: 20934501
[TBL] [Abstract][Full Text] [Related]
2. Chimeric advanced drug delivery nano systems (chi-aDDnSs) for shikonin combining dendritic and liposomal technology.
Kontogiannopoulos KN; Assimopoulou AN; Hatziantoniou S; Karatasos K; Demetzos C; Papageorgiou VP
Int J Pharm; 2012 Jan; 422(1-2):381-9. PubMed ID: 21979251
[TBL] [Abstract][Full Text] [Related]
3. A new chimeric drug delivery nano system (chi-aDDnS) composed of PAMAM G 3.5 dendrimer and liposomes as doxorubicin's carrier. In vitro pharmacological studies.
Gardikis K; Fessas D; Signorelli M; Dimas K; Tsimplouli C; Ionov M; Demetzos C
J Nanosci Nanotechnol; 2011 May; 11(5):3764-72. PubMed ID: 21780367
[TBL] [Abstract][Full Text] [Related]
4. Thermodynamic and structural characterization of Liposomal-Locked in-Dendrimers as drug carriers.
Gardikis K; Hatziantoniou S; Signorelli M; Pusceddu M; Micha-Screttas M; Schiraldi A; Demetzos C; Fessas D
Colloids Surf B Biointerfaces; 2010 Nov; 81(1):11-9. PubMed ID: 20638250
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin-PAMAM dendrimer complex attached to liposomes: cytotoxic studies against human cancer cell lines.
Papagiannaros A; Dimas K; Papaioannou GT; Demetzos C
Int J Pharm; 2005 Sep; 302(1-2):29-38. PubMed ID: 16099117
[TBL] [Abstract][Full Text] [Related]
6. New drug delivery nanosystem combining liposomal and dendrimeric technology (liposomal locked-in dendrimers) for cancer therapy.
Gardikis K; Hatziantoniou S; Bucos M; Fessas D; Signorelli M; Felekis T; Zervou M; Screttas CG; Steele BR; Ionov M; Micha-Screttas M; Klajnert B; Bryszewska M; Demetzos C
J Pharm Sci; 2010 Aug; 99(8):3561-71. PubMed ID: 20564386
[TBL] [Abstract][Full Text] [Related]
7. The liposomal formulation of doxorubicin.
Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
[TBL] [Abstract][Full Text] [Related]
8. Coformulated N-octanoyl-glucosylceramide improves cellular delivery and cytotoxicity of liposomal doxorubicin.
Veldman RJ; Koning GA; van Hell A; Zerp S; Vink SR; Storm G; Verheij M; van Blitterswijk WJ
J Pharmacol Exp Ther; 2005 Nov; 315(2):704-10. PubMed ID: 16040815
[TBL] [Abstract][Full Text] [Related]
9. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
[TBL] [Abstract][Full Text] [Related]
10. A duplex oligodeoxynucleotide-dendrimer bioconjugate as a novel delivery vehicle for doxorubicin in in vivo cancer therapy.
Lee IH; Yu MK; Kim IH; Lee JH; Park TG; Jon S
J Control Release; 2011 Oct; 155(1):88-95. PubMed ID: 20854858
[TBL] [Abstract][Full Text] [Related]
11. Advanced drug delivery nanosystems (aDDnSs): a mini-review.
Demetzos C; Pippa N
Drug Deliv; 2014 Jun; 21(4):250-7. PubMed ID: 24134707
[TBL] [Abstract][Full Text] [Related]
12. The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors.
Mayer LD; Dougherty G; Harasym TO; Bally MB
J Pharmacol Exp Ther; 1997 Mar; 280(3):1406-14. PubMed ID: 9067330
[TBL] [Abstract][Full Text] [Related]
13. Intracellular drug delivery by sulfatide-mediated liposomes to gliomas.
Shao K; Hou Q; Duan W; Go ML; Wong KP; Li QT
J Control Release; 2006 Oct; 115(2):150-7. PubMed ID: 16963144
[TBL] [Abstract][Full Text] [Related]
14. Microbial biosensors to monitor the encapsulation effectiveness of Doxorubicin in chimeric advanced Drug Delivery Nano Systems: A calorimetric approach.
Gardikis K; Signorelli M; Ferrario C; Schiraldi A; Fortina MG; Hatziantoniou S; Demetzos C; Fessas D
Int J Pharm; 2017 Jan; 516(1-2):178-184. PubMed ID: 27845212
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
Allen TM; Mumbengegwi DR; Charrois GJ
Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
[TBL] [Abstract][Full Text] [Related]
16. Zirconium phosphate nano-platelets: a novel platform for drug delivery in cancer therapy.
Díaz A; Saxena V; González J; David A; Casañas B; Carpenter C; Batteas JD; Colón JL; Clearfield A; Hussain MD
Chem Commun (Camb); 2012 Feb; 48(12):1754-6. PubMed ID: 22218458
[TBL] [Abstract][Full Text] [Related]
17. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells.
Kobayashi T; Ishida T; Okada Y; Ise S; Harashima H; Kiwada H
Int J Pharm; 2007 Feb; 329(1-2):94-102. PubMed ID: 16997518
[TBL] [Abstract][Full Text] [Related]
18. [The in vitro cytotoxicity and in vivo toxicity of doxorubicin antiresistant stealth liposomes].
Wang JC; Liu XY; Lü WL; Lee HS; Goh BC; Zhang Q
Yao Xue Xue Bao; 2005 May; 40(5):475-80. PubMed ID: 16220797
[TBL] [Abstract][Full Text] [Related]
19. Novel hyaluronic acid (HA) coated drug carriers (HCDCs) for human breast cancer treatment.
Hyung W; Ko H; Park J; Lim E; Park SB; Park YJ; Yoon HG; Suh JS; Haam S; Huh YM
Biotechnol Bioeng; 2008 Feb; 99(2):442-54. PubMed ID: 17625788
[TBL] [Abstract][Full Text] [Related]
20. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles.
Azarmi S; Tao X; Chen H; Wang Z; Finlay WH; Löbenberg R; Roa WH
Int J Pharm; 2006 Aug; 319(1-2):155-61. PubMed ID: 16713150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
